Stock JAZZ PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Jazz Pharmaceuticals, Inc. Nasdaq

Equities

US4721471070

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Jazz Pharmaceuticals, Inc.
Jul. 10 Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer CI
Jul. 09 RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Jazz Pharmaceuticals Hosts Discussion of Healthcare Inequities in the U.S. To Honor Juneteenth
AQ
Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
PR
Jazz Pharmaceuticals Publishes 2023 Corporate Sustainability and Social Impact Report: Progress, Responsibility and Innovation
AQ
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
PR
Jazz Pharmaceuticals : 2023 Annual Report
PU
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)
AQ
Jazz Pharmaceuticals plc - Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
AQ
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
PR
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR
Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism
PR
Jazz Pharmaceuticals : Corporate Overview
PU
Jazz Pharmaceuticals : Announces First Quarter 2024 Financial Results
PU
Jazz: Q1 Earnings Snapshot
AQ
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
PR
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
PR
Jazz Pharmaceuticals to Present Data across Growing Oncology Pipeline and Portfolio at ASCO 2024
AQ
The PharmaMar Group presents financial results for the first quarter of 2024
AQ
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
PR
Jazz Pharmaceuticals : Zanidatamab R&D Day
PU
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. Stock
  5. News Jazz Pharmaceuticals, Inc.
  6. Press Releases